Improving Equitability and Inclusion for Testing and Detection of Lead Poisoning in US Children

Child lead poisoning, the longest-standing child public health epidemic in US history, is associated with socioeconomic inequity and perpetuates health inequality. Removing lead from children’s environments (“primary prevention”) is and must remain the definitive solution for ending child lead poiso...

全面介绍

Saved in:
书目详细资料
主要作者: Gutierrez Vega, Marisela
其他作者: Sobin, Christina, Flores-Montoya, Gisel, Del Rio, Michelle, Alvarez, Juan M., Obeng, Alexander, Avila, Jaleen, Hettiarachchi, Ganga
格式: Artículo
语言:en_US
出版: 2023
主题:
在线阅读:https://doi.org/10.1111/1468-0009.12596
https://onlinelibrary.wiley.com/doi/10.1111/1468-0009.12596
https://pubmed.ncbi.nlm.nih.gov/36717973/
标签: 添加标签
没有标签, 成为第一个标记此记录!
实物特征
总结:Child lead poisoning, the longest-standing child public health epidemic in US history, is associated with socioeconomic inequity and perpetuates health inequality. Removing lead from children’s environments (“primary prevention”) is and must remain the definitive solution for ending child lead poisoning. Until that goal can be realized, protecting children’s health necessarily depends on the adequacy of our methods for testing and detection. Current methods for testing and detection, however, are no longer suited to the demographics and magnitude of the problem. We discuss the potential deployment and feasibility of a three-pronged revision of current practices including: 1) acceptance of capillary samples for final determination of lead poisoning, with electronic documentation of “clean” collection methods submitted by workers who complete simple Centers for Disease Control and Prevention–endorsed online training and certification for capillary sample collection; 2) new guidance specifying the analysis of capillary samples by inductively coupled plasma mass spectrometry or graphite furnace atomic absorption spectrometry with documented limit of detection ≤0.2 μg/dL; and 3) adaptive “census tract–specific” universal testing and monitoring guidance for children from birth to 10 years of age. These testing modifications can bring child blood lead level (BLL) testing into homes and communities, immediately increasing our national capacity for inclusive and equitable detection and monitoring of dangerous lower-range BLLs in US children.